Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
C-Rad AB Class B ( ($SE:CRAD.B) ) just unveiled an update.
C-RAD AB reported a positive earnings trend for the third quarter of 2025, with a 12% increase in revenue and a 19% EBIT margin, driven by strong demand for their SGRT solutions and significant growth in their services sector. Despite geopolitical uncertainties affecting sales processes, the company is taking proactive steps to strengthen its market presence, with notable growth in the EMEA region and strategic partnerships aimed at enhancing patient safety in radiotherapy.
The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.
More about C-Rad AB Class B
C-RAD AB is a company specializing in the medical technology industry, focusing on Surface Guided Radiation Therapy (SGRT) solutions. They provide products and services that enhance automation and efficiency in radiation therapy, benefiting both patients and clinics by improving treatment precision and reducing the number of sessions required.
Average Trading Volume: 40,835
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.12B
See more data about CRAD.B stock on TipRanks’ Stock Analysis page.